Applying genome-wide association technology to brain diseases enables the discovery of lncRNas targets for gene therapy
Moataz Dowaidar
Abstract
The role of LncRNAs is unique in that, after the initial transcription step, which impacts multiple types of gene expression, subsequent stages influence a variety of brain diseases. The timely and ordered production and regulation of LncRNAs is critical for cellular homeostasis to be maintained. A recent study focused on identifying unique lncRNAs as potential therapeutic targets. Brain diseases (BDs) and brain cancers are known to have LncRNA alterations influencing various basic neuronal cell characteristics. Furthermore, exosomal-lncRNAs have been found to promote cancer drug resistance. Changes in lncRNA expression and location can lead to brain sickness, which is consistent with their crucial role. Brain illnesses are frequently linked to lncRNA abnormalities. The use of lncRNAs in targeted therapies has emerged, and these ideas are based on the assumption that when BDs involve abnormal lncRNA activity, this event is linked to a second effect activation in a genetic system.As a result, uncovering novel lncRNA roles in BDs as well as brain developmental anomalies might provide a unique opportunity to design therapeutic aims. Examined the present state of knowledge on lncRNAs in various BDs, modulation and regulation of lncRNAs, and lncRNA participation in BD processing. Despite the fact that genetic and pharmacological studies have shed light on the various roles of lncRNAs and molecular components, many questions remain unanswered. The timing and location of brain-specific lncRNA transcription and translocation, for example, are unknown. Furthermore, the genetic foci of lncRNAs as well as their distinct phenotypes are unknown.lncRNAs can now be tested and targeted in BDs thanks to the development of GWAS technology. Such study might lead to the discovery of novel targets for drug development that are both efficient and effective in the treatment of BDs.